TP53 and neoplasm: We also find that pharmacological inhibition of the Cxcr1/2 signaling pathway decreases neutrophil recruitment, reduces early proliferation of tumor-initiating cells, and reduces subsequent pre-tumorous mass formation in a p53 null background.